Rochester Network Lead Academic Participating Site

项目摘要/摘要 罗切斯特大学威尔莫特癌症研究所是一个健康和研究机构，非常适合实现 NCI NCTN作为领先学术网站的目标。我们作为U10资助的成员的长期活动 ECOG(1968-2002)和SWOG(2002-2012)以及我们在过去5年中对NCTN试验的奉献 表明我们对癌症临床和转化性实验室研究的持续投资和承诺， 特别是晚期癌症临床试验的发展和收益。在这样一个时代，生物学既是 癌症的发展和新的治疗策略的开发已经变得更加复杂，需要 多学科的调查团队和广泛的组织库和相关研究，我们的翻译 科学的计划和对NCTN计划的奉献是最终成功的关键。 我们的临床试验计划由一个领导小组和跨医学系的教职员工组成 (血液学和内科肿瘤学)、外科、泌尿科、放射肿瘤学和妇产科 都在NCTN计划中投入了大量资金。NCTN试验结构是我们临床试验的关键组成部分 办公室，并利用多学科疾病工作组作为方案管理的中心，确保 适当和基础广泛的专业知识。我们在NCTN小组中的领导角色，委员会成员， 出版记录和科学成就为我们继续为终极质量做出贡献奠定了良好的基础 NCTN的使命。我们在协调合作小组研究方面有很长的历史，并将继续这样做， 建立在罗切斯特大学进行的前期工作的基础上，也在全美范围内合作 基于NCTN组。 在2014至2017年间，我们能够快速启动NCTN临床试验，积累了100多名患者 平均每年提交高质量数据，并以高效方式提交高质量的数据。因此，罗切斯特被认可了 被NCI评为高绩效网站。我们计划在整个网络中进一步加强这一努力，因为我们的 扩大区域存在，同时继续专注于代表性不足的患者群体，包括 青少年/青壮年和老年人口。我们在几项重要研究方面领先于全国， 包括对罕见疾病进行的研究，以及我们为增加少数群体的收益所做的努力 应计入代表我们全体人口的临床试验。罗切斯特大学致力于 并将继续致力于制定和进行相关的试验 最高级别。

PROJECT SUMMARY/ABSTRACT The University of Rochester, Wilmot Cancer Institute is a health and research institute ideally suited to achieve the goals of the NCI NCTN as a Lead Academic Site. Our longstanding activity as U10-funded members of ECOG (1968-2002) and SWOG (2002-2012) as well as our dedication to NCTN trials over the past 5 years indicate our continued investment in and commitment to clinical and translational laboratory research in cancer, particularly the development of and accrual to late-phase Cancer Clinical Trials. In an era where both the biology of cancer and development of novel therapeutic strategies have become more complex, requiring multidisciplinary teams of investigators and extensive tissue banking and correlative studies, our translational scientific program and dedication to the NCTN program is critical for ultimate success. Our Clinical Trials Program consists of a leadership group and faculty across the departments of medicine (hematology and medical oncology), surgery, urology, radiation oncology and obstetrics and gynecology who are highly invested in the NCTN program. The NCTN trials structure is a key component of our Clinical Trials Office, and utilizes multidisciplinary disease Working Groups as the hub for protocol management, ensuring appropriate and broad-based expertise. Our leadership roles within the NCTN groups, committee membership, publication record, and scientific achievements position us well for continued quality contributions to the ultimate mission of NCTN. We have a long history of coordinating cooperative group studies and continue to do so, building on preliminary work conducted at University of Rochester but also collaborating across all of the US based NCTN groups. Between 2014 and 2017, we were able to activate NCTN clincal trials quickly, accrued more than 100 patients annually on average, and submitted high quality data in an efficient manner. As such, Rochester was recogized as a High Performing Site by the NCI. We plan to further increase this effort across the Network given our expanded regional presence, while continuing to focus on underrepresented patient groups including the adolesent/young adult and geriatric populations. We have led the country in accrual to several important studies, including studies conducted on rare diseases, and our efforts to enhance minority accrual have resulted in accrual to clinical trials representative of our overall population. The University of Rochester is dedicated to the mission of the NCTN and will continue to contibute to the development and conduct of associated trials at the highest level.